Related Experiment Video

Updated: May 30, 2025

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.5K

NRG1 Fusions: The New Kid on the Block

Brinda Gupta1, Leila Borghaei2, Stephen V Liu3

  • 1Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, Washington, DC, 20007, USA.

Current Oncology Reports
|January 31, 2025
PubMed
Abstract

Insights

Neuregulin 1 (NRG1) fusions drive cancer growth in non-small cell lung cancer (NSCLC). Targeted therapies, like zenocutuzumab, offer effective treatment for NRG1 fusion-positive NSCLC, with new agents in development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Neuregulin 1 (NRG1) fusions are rare oncogenic drivers in various cancers, notably non-small cell lung cancer (NSCLC).
  • These fusions activate HER signaling pathways, promoting tumor progression, invasion, and metastasis.
  • NRG1 fusion-positive NSCLC exhibits poor response to conventional therapies like immunotherapy and chemotherapy.

Purpose of the Study:

  • To review the biology and detection methods for NRG1 fusions.
  • To explore the therapeutic landscape for NSCLC harboring NRG1 fusions.
  • To summarize current and emerging treatment strategies for NRG1 fusion-driven NSCLC.

Main Methods:

  • Literature review of studies on NRG1 fusions in NSCLC.
  • Analysis of current therapeutic strategies and ongoing clinical trials.
  • Summary of diagnostic approaches for identifying NRG1 fusions.

Main Results:

  • Zenocutuzumab, a bispecific antibody targeting HER2 and HER3, is the first FDA-approved treatment for previously treated NRG1 fusion-positive NSCLC.
  • NRG1 fusions are rare but actionable drivers treatable with targeted therapies.
  • Multiple novel NRG1 fusion-directed therapies are under investigation.

Conclusions:

  • NRG1 fusions represent a targetable subset of NSCLC.
  • Targeted therapies, including zenocutuzumab, demonstrate efficacy in NRG1 fusion-positive NSCLC.
  • Ongoing research is expanding treatment options for this patient population.
Keywords:
HER2HER3NRG1 fusionsNSCLCTargeted therapy

More Related Videos

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models10:04

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

11.9K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.7K

Related Concept Videos

Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.2K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
4.9K